Thank you for subscribing!
Finfeed Archived Mar 30, 2020
Shares in Genetic Signatures Limited (ASX: GSS) were up 50% at one stage on Monday morning as management announced that the company had supplemented its existing assays to specifically identify the 2019 novel strain of coronavirus (SARS-CoV-2), the virus that causes COVID-19.
Finfeed Archived Mar 23, 2020
The US Patent and Trademark Office (USPTO) has issued a notice of allowance for issuance of a new key patent for clinical-stage regenerative medicine company Regeneus Ltd's (ASX: RGS) lead stem cell platform technology Progenza.
Finfeed Archived Mar 20, 2020
Regeneus Ltd (ASX: RGS) today received a non-refundable milestone payment of ¥100M (approx. A$1.6M) from Kyocera Corporation (TYO:6971).
Finfeed Archived Mar 18, 2020
OncoSil Medical Ltd’s (ASX: OSL) OncoSil™ device has reached a significant milestone, receiving Breakthrough Device Designation by the US FDA for the treatment of unresectable locally advanced pancreatic cancer.
Get expert stock analysis direct in your inbox
Finfeed Archived Mar 03, 2020
Clinical stage regenerative medicine company Regeneus Ltd (ASX:RGS) has signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in the life sciences industry.
Finfeed Archived Feb 27, 2020
The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd (ASX:OSL) as it flags the finalisation of commercialisation plans for its OncoSil™ device ahead of CE marking early in 2020.
Finfeed Archived Feb 03, 2020
With the recent emergence in China of a new virulent strain of the Coronavirus, and the well-publicised impacts of that virus on human health, Zoono Group Limited (ASX:ZNO) has been inundated by public and shareholder enquiry concerning its products and their effectiveness in combatting the spread of the new virus.
Next Investors Archived Jan 30, 2020
OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.
Finfeed Archived Jan 08, 2020
PharmAust Limited’s (ASX:PAA) wholly-owned subsidiary, Epichem Pty Ltd, has been awarded an extension to its current contract with Drugs for Neglected Diseases initiative.
Join Our Mailing List
